Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma
Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma
This phase II trial studies how well ibrutinib and rituximab given together with venetoclax
 and combination chemotherapy work in treating patients with newly diagnosed mantle cell
 lymphoma. Ibrutinib may stop the growth of tumor cells by blocking some of the enzymes needed
 for cell growth. Rituximab is a monoclonal antibody that may interfere with the ability of
 cancer cells to grow and spread. Venetoclax may stop the growth of cancer cells by blocking
 Bcl-2, a protein needed for cancer cell survival. Drugs used in chemotherapy such as,
 cyclophosphamide, vincristine, doxorubicin, and dexamethasone, work in different ways to stop
 the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by
 stopping them from spreading. Giving ibrutinib, rituximab, and venetoclax together with
 combination chemotherapy may work better in treating patients with mantle cell lymphoma.
PRIMARY OBJECTIVE:

 I. To determine the complete response rate of the ibrutinib plus rituximab combination
 followed by venetoclax in newly diagnosed young mantle cell lymphoma (MCL) patients.

 SECONDARY OBJECTIVES:

 I. To determine the safety profile of the ibrutinib plus rituximab combination followed by
 venetoclax in newly diagnosed young MCL patients.

 II. To evaluate the progression-free survival and overall survival time of the ibrutinib plus
 rituximab combination followed by venetoclax and hyper-fractionated cyclophosphamide,
 vincristine sulfate, doxorubicin hydrochloride, and dexamethasone (hyper-CVAD) in newly
 diagnosed young MCL patients.

 EXPLORATORY OBJECTIVE:

 I. Developing a novel biomarker for minimal residual disease (MRD) assay using the
 circulating tumor deoxyribonucleic acid (DNA) (ctDNA) assay on a customized capture
 sequencing gene panel for MCL using serial plasma samples collected in this trial.

 OUTLINE:

 PART I: Patients receive ibrutinib orally (PO) once daily (QD) on days 1-28 and receive
 rituximab intravenously (IV) over 4-8 hours on days 1, 8, 15, and 22 of cycle 1 and on day 1
 of cycles 3-12. Patients also receive venetoclax PO QD on days 1-28 of cycles 5-12. Treatment
 repeats every 28 days for up to 12 cycles in the absence of disease progression or
 unacceptable toxicity.

 PART II: Patients are assigned to 1 of 3 groups depending on risk status.

 GROUP I:

 COMBINATION CHEMOTHERAPY: Patients receive rituximab IV over 6 hours on day 1, dexamethasone
 PO or IV on days 1-4, cyclophosphamide IV over 3 hours twice daily (BID) on days 2-4, and
 doxorubicin hydrochloride IV over 24 hours and vincristine sulfate IV over 15-30 minutes on
 day 5 of odd-numbered cycles (1 and 3). Patients also receive rituximab IV over 6 hours on
 day 1, methotrexate IV over 24 hours on day 2, and cytarabine IV over 2 hours BID on days 3-4
 of even-numbered cycles (2 and 4). Treatment repeats every 28 days for up to 4 cycles in the
 absence of disease progression or unacceptable toxicity.

 MAINTENANCE THERAPY: Patients receive ibrutinib and venetoclax PO QD on days 1-28, and
 rituximab IV over 4-8 hours on day 1 of every other month. Cycles repeat every 28 days for up
 to 24 months in the absence of disease progression or unacceptable toxicity.

 GROUP II: Patients receive combination chemotherapy as in group I. Treatment repeats every 28
 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity.
 Patients also receive maintenance therapy as in group I.

 GROUP III: Patients receive maintenance therapy as in group I.

 After completion of study treatment, patients are followed up at 30 days, every 4 months for
 2 years, every 6 months for 2 years, and then annually for up to 5 years.
Inclusion Criteria:

 -  Confirmed diagnosis of mantle cell lymphoma with CD20 positivity in tissue biopsy

 -  MCL patients must have a clinical indication to start systemic therapy. Symptoms and
 features of MCL include any of the following: a) B-symptoms, b) Mantle Cell Lymphoma
 International Prognostic Index (MIPI) > 3, c) Ki 67 >= 30%, d) bulky tumors > 10 cm or
 in case of >= 2 tumors, each >= 5 cm in diameter, e) disease threatening organ
 function, f) elevated lactate dehydrogenase (LDH), g) peripheral blood (PB) white
 blood cell (WBC) > 50,000, h) pancytopenia due to bone marrow MCL, i) patient's choice
 due to anxiety; j) pain due to lymphoma; k) somatic mutations in the TP53, NSD2 or
 NOTCH genes; l) size of spleen >= 20 cm

 -  Newly diagnosed MCL with no prior therapy

 -  Sign (or their legally-acceptable representatives must sign) an informed consent
 document indicating that they understand the purpose of and procedures required for
 the study, including biomarkers, and are willing to participate in the study

 -  Bi-dimensional measurable disease using both computed tomography (CT) scan and/or
 positron emission tomography (PET)-CT or gastrointestinal biopsies, CT
 gastrointestinal, bone marrow or spleen only patients are allowable

 -  Eastern Cooperative Oncology Group (ECOG) performance status of 2 or less

 -  Absolute neutrophil count (ANC) >= 1000/mm^3 independent of growth factor support

 -  Platelets >= 100,000/mm^3 or >= 50,000/mm^3 if bone marrow involvement without
 necessitating transfusion

 -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x upper limit
 of normal (ULN)

 -  Total bilirubin =< 1.5 x ULN unless bilirubin rise is due to Gilbert's syndrome or of
 non-hepatic origin

 -  Creatinine clearance (CLcr) > 50 mL/min

 -  Cardiac ejection fraction >= 50% by echocardiogram (ECHO) or multigated acquisition
 (MUGA)

 -  Disease free of prior malignancies with exception of currently treated basal cell,
 squamous cell carcinoma of the skin, carcinoma "in situ" of the cervix or breast, or
 other malignancies in remission (including prostate cancer patients in remission from
 radiation therapy, surgery or brachytherapy), not actively being treated with life
 expectancy of greater than 3 years. Principal investigator (PI) can use clinical
 judgement in the best interest of patients

 -  Females of childbearing potential (FCBP) must have a negative serum or urine pregnancy
 test (within 28 days of initiation of protocol therapy) and must be willing to use
 acceptable methods of birth control during and after the study consistent with local
 regulations regarding the use of birth control methods for subjects participating in
 clinical trials. Men must agree to use a latex condom during sexual contact with a
 female of childbearing potential even if they have had a successful vasectomy. Men
 must agree to not donate sperm during and after the study. For females, these
 restrictions apply for 1 month after the last dose of study drug. For males, these
 restrictions apply for 3 months after the last dose of study drug

 -  A female of childbearing potential is a sexually mature woman who: 1) has not
 undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally
 postmenopausal for at least 24 consecutive months (i.e., has had menses at any
 time in the preceding 24 consecutive months).

 Exclusion Criteria:

 -  Any serious medical condition including but not limited to, uncontrolled hypertension,
 uncontrolled diabetes mellitus, active/symptomatic coronary artery disease, chronic
 obstructive pulmonary disease (COPD), renal failure, active hemorrhage, laboratory
 abnormality, or psychiatric illness that, in the investigators opinion, places the
 patient at unacceptable risk or would prevent the subject from signing the informed
 consent form

 -  Pregnant or breast-feeding females

 -  Known human immunodeficiency virus (HIV) infection (HIV testing is not required)

 -  Evidence of other clinically significant uncontrolled condition(s) including, but not
 limited to:

 -  Uncontrolled and/or active systemic infection (viral, bacterial or fungal)

 -  Chronic hepatitis B virus (HBV) or hepatitis C (HCV) requiring treatment. Note:
 subjects with serologic evidence of prior vaccination to HBV (i.e. hepatitis B
 surface [HBs] antigen negative-, anti-HBs antibody positive and anti-hepatitis B
 core [HBc] antibody negative) or positive anti-HBc antibody from intravenous
 immunoglobulins (IVIG) may participate

 -  Treatment with any of the following within 7 days prior to the first dose of study
 drug:

 -  Steroid therapy for anti-neoplastic intent

 -  Moderate or strong cytochrome P450 3A (CYP3A) inhibitors

 -  Moderate or strong CYP3A inducers

 -  Administration or consumption of any of the following within 3 days prior to the first
 dose of study drug:

 -  Grapefruit or grapefruit products

 -  Seville oranges (including marmalade containing Seville oranges)

 -  Star fruit

 -  Patients with active hepatitis B infection (not including patients with prior
 hepatitis B vaccination; or positive serum hepatitis B antibody). Known hepatitis C
 infection is allowed as long as there is no active disease and is cleared by
 gastrointestinal (GI) consultation

 -  Central nervous system with mantle cell lymphoma

 -  Significant neuropathy (grades 3 to 4, or grade 2 with pain) within 14 days prior to
 enrollment

 -  Contraindication to any of the required concomitant drugs or supportive treatments or
 intolerance to hydration due to preexisting pulmonary or cardiac impairment including
 pleural effusion requiring thoracentesis or ascites requiring paracentesis unless due
 to lymphoma

 -  Malabsorption syndrome, disease significantly affecting gastrointestinal function, or
 resection of the stomach or small bowel or ulcerative colitis, symptomatic
 inflammatory bowel disease, or partial or complete bowel obstruction, or any other
 gastrointestinal condition that could interfere with the absorption and metabolism of
 ibrutinib

 -  Major surgery within 4 weeks of initiation of therapy or a wound that has not fully
 healed within 4 weeks of randomization. Clearance letter from primary physician
 required

 -  Requires anticoagulation with warfarin or equivalent vitamin K antagonist

 -  Requires chronic treatment with strong CYP3A inhibitors

 -  Patients with New York Health Association (NYHA) Class III and IV heart failure,
 myocardial infarction in the preceding 6 months, and significant conduction
 abnormalities, including but not limited to left bundle branch block, 2nd degree
 atrioventricular (AV) block type II, 3rd degree block, QT prolongation (corrected QT
 [QTc] > 500 msec), sick sinus syndrome, ventricular tachycardia, symptomatic
 bradycardia (heart rate < 50 bpm), hypotension, light headedness and syncope,
 persistent and uncontrolled atrial fibrillation

 -  Recent placement of a stent and by recommendation of their cardiologist need to stay
 on anticoagulants such as warfarin or equivalent vitamin K antagonist

 -  Acute infection requiring treatment (IV antibiotics, antivirals, or antifungals)
 within 14 days prior to initiation of therapy

 -  Child-Pugh class B or C are excluded

 -  Vaccinated with live, attenuated vaccines within 4 weeks of randomization